Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTEM versus FOLFIRI in MGMT-methylated, RAS-mutated advanced colorectal cancer after oxaliplatin
2014-002417-36Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jul 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine, temozolomide, fluorouracil and irinotecan in colorectal cancer (CRC) (2 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Progression-free survival. Started Jul 2014; status: completed.
02
Drugs
capecitabinetemozolomidefluorouracilirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2014-002417-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002417-36.